



Diagonal Bio expands equine panel with addition of strangles

Diagonal Bio AB ("Diagonal Bio" or the "Company"), with the point of care diagnostic system LAMPlify, announces the positive progress of a test for the bacteria *Streptococcus equi* subs. *equi*. This bacteria causes strangles ("kvarka" in Swedish), and is a highly contagious equine pathogen. This new test is designed to work with the existing LAMPlify equine respiratory virus panel to provide broader coverage of threats to equine health.

The new test has shown promising internal results with samples sourced from multiple locations in Sweden and Denmark, on samples from infected and healthy horses. Diagonal Bio is now looking for opportunities to validate this new offering in point-of-care settings with existing or new commercial pilots, before adding this marker to the commercial LAMPlify equine panel.

"Strangles is a notifiable disease in Sweden, i.e. it must be reported to Svenska Veterinäransalten (SVA), and a major concern to equine health worldwide. By adding this test to our LAMPlify equine panel, we hope to provide veterinarians, trainers and horse owners with the tools needed to detect strangles early, before it spreads, minimizing costly decontamination and avoiding protracted shutdowns", says Karin Wehlin, CEO of Diagonal Bio.

Over the past 12 months, Diagonal Bio has shortened the development time for new markers from 24 weeks to around 4 weeks through the development of in-house capabilities in identifying primers and validating these on live samples. This exceptionally rapid development process will enable Diagonal Bio to quickly grow its swab testing portfolio of markers and respond to needs from customers, which opens significant potential for expansion into new market segments.

For additional information about Diagonal Bio, please contact:

Karin Wehlin, CEO

Phone: +46 70 305 24 88

E-mail: kw@diagonalbio.com

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.